| Dan F Kreuzer, DO | |
|
383 Garden Ave, Holland, MI 49424-9602 | |
| (616) 494-8271 | |
| (616) 494-8273 |
| Full Name | Dan F Kreuzer |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 383 Garden Ave, Holland, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053463646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 5101008291 (Michigan) | Primary |
| 2083X0100X | Preventive Medicine - Occupational Medicine | 5101008291 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dan F Kreuzer, DO 2946 146th Ave Sw, Byron Center, MI 49315-9124 Ph: (616) 896-8129 | Dan F Kreuzer, DO 383 Garden Ave, Holland, MI 49424-9602 Ph: (616) 494-8271 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Unlike birds and amphibians, mammals can't recover lost hearing. In people, the cells of the inner ear responsible for detecting sound and transmitting those signals to the brain form during early stages of development and can't be replaced if lost due to illness, injury or aging.
Molina Healthcare, Inc. announced today that, based on its preliminary unaudited analysis, it expects to report a loss per diluted share for the fourth quarter of 2009 in the range of $0.10 to $0.25, and earnings for the year ended December 31, 2009, in the range of $1.12 to $1.26.
EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.
Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.
› Verified 6 days ago
Dr. Don R. Judd, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 4688 Sailview Dr, Holland, MI 49423 Phone: 616-335-5662 | |
Dr. Duane Frank Wisk, D.O. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 960 Meadow Ridge Dr, Holland, MI 49424 Phone: 313-641-0676 Fax: 616-392-8992 | |
Dr. Paul A Heidel, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 12251 James St, Suite 400, Holland, MI 49424 Phone: 616-494-5548 Fax: 616-393-5643 | |
Mr. Joseph Kenneth Postma, M.D. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 602 Michigan Ave, Holland, MI 49423 Phone: 616-546-4950 |